Sclerostin levels in uremic patients: a link between bone and vascular disease. (27th May 2016)

• Record Type: Journal Article
• Authors: Bruzzese, Annamaria; Lacquaniti, Antonio; Cernaro, Valeria; Ricciardi, Carlo Alberto; Loddo, Saverio; Romeo, Adolfo; Montalto, Gaetano; Costantino, Giuseppe; Torre, Francesco; Pettinato, Giuseppina; Salamone, Ignazio; Aloisi, Carmela; Santoro, Domenico; Buemi, Michele
• Is Part Of: Renal failure. Volume 38:Number 5(2016)
• Page Start: 759
• Page End: 764
• Publication Date: 2016-05-27
• Subjects: Acetate Free Bio-filtration -- atherosclerotic disease -- Chronic kidney disease-mineral and bone disorder -- sclerostin -- vascular calcification; Chronic renal failure -- Periodicals; Acute renal failure -- Periodicals; Uremia -- Periodicals; 616.614005
• DOI: 10.3109/0886022X.2016.1160207
• Languages: English
• ISSNs: 0886-022X

Abstract

Abstract: Sclerostin is a marker of low-turnover bone disease in end stage renal disease patients. The aim of this study was to evaluate serum sclerostin in uremic patients, analyzing its behavior during a single hemodialysis session. Twenty-one adult patients on intermittent hemodialysis treatment were enrolled. Acetate Free Bio-filtration (AFB) was the technique employed. Uremic patients were characterized by higher levels of serum sclerostin when compared with values observed in healthy subjects. Sclerostin assessed in pre-dialysis samples was 1.4 ± 1.02 ng/mL, whereas, in post dialysis samples, a reduction of sclerostin values was observed (0.8 ± 0.6 ng/mL; p : 0.008). Sclerostin correlated with parameters of dialysis adequacy, such as creatinine levels and Kt / V values, and it was significantly associated with atherosclerotic disease. Receiver operating characteristics analysis revealed a good diagnostic profile in identifying atherosclerotic disease. Sclerostin, a full dialyzable substance during AFB dialysis, is closely associated with atherosclerotic disease. Its reduction obtained through AFB could represent a defensive mechanism, improving vascular disease and renal osteodystrophy.